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Introduction
Autism is a complex disorder marked by impairment of verbal communications, 
social relationship problems, repetitive behaviors, and restrictive interests. Its 
etiology is unclearly understood and there is debate about its pathogenesis. There 
are no effective therapies for autism. Novel therapeutic interventions for treating 
autism are therefore a priority. Autism is additionally highly comorbid with epilepsy 
(OR=22.2; 95% CI=16.8-29.3) (1), but treatment refractory epilepsy in autism 
occurs in up to 33.9% of individuals (2). Complicating this, outcomes of surgical 
and vagus nerve stimulator (VNS) implantation in patients with both autism and 
epilepsy are less effective than in other treatment refractory epilepsy patients (2). 
Glutamate is a crucial neurotransmitter in the brain. It is released from cells into the 
extracellular Àuid and then removed by glutamate transporters. This transportation 
regulates excitatory synaptic transmissions. While the level of glutamine is 
decreased, glutamate level is increased in autism and tryptophan in autism (3). 
The excitatory amino acid transporter of EAAT2 (or GLT1) is one of the main 
glutamate transporters in brain. About 90% of glutamate transporters in brain are 
of the EAAT2 type (4). Excitatory amino acid transporters keep the extracellular 
glutamate level lower than the neurotoxic level, and GLT-1 is the major determinant 
of glutamate level in extracellular Àuid. The decreased expression and function 
of astrocyte glutamate transporters enhances the levels of extracellular glutamate 
in epilepsy and Tuberous Sclerosis Complex (5). Tuberous Sclerosis Complex is 
usually co-morbid with epilepsy and autism. Astrocyte glutamate transporters are 
de¿cient in animal models of epilepsy in Tuberous Sclerosis Complex (6). This 
abnormality is also reported in human and animal models of epilepsy. In addition, 
targeting astrocytic mechanisms has been introduced as a novel treatment approach 
for epilepsy and TSC (6).  
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CASE REPORT
Abstract
Autism is a disorder of unknown etiology. There are few FDA approved 
medications for treating autism. Co-occurring autism and epilepsy is common, 
and glutamate antagonists improve some symptoms of autism. Ceftriaxone, a 
beta-lactam antibiotic, increases the expression of the glutamate transporter 1 
which decreases extracellular glutamate levels. It is hypothesized that modulating 
astrocyte glutamate transporter expression by ceftriaxone or ce¿xime might 
improve some symptoms of autism. This case report of a child with autism and 
epilepsy suggests a decrease in seizures after taking ce¿xime
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The beta-lactam antibiotics ce¿xime and ceftriaxone are 
third-generation cephalosporins. Ceftriaxone increases 
GLT1/EAAT2 expression (7). Ce¿xime and ceftriaxone 
are beta lactam antibiotics, and the latter improves the 
expression of glutamate transporter (GLT-1). Glutamate 
neurotoxicity may contribute as a pathological 
mechanism for autism (8). There is an abnormal GABA to 
glutamate ratio (8) suggesting an imbalance of inhibitory 
and excitatory systems in the neurobiology of autism 
(9). Glutamate synthesis inhibition attenuates neurotoxic 
activity in Rett’s syndrome (10). It is suggested that 
attenuation of the hyperglutaminergic state in autism 
may improve symptoms (11). Equally, up regulation of 
the GABAergic system is proposed to have utility (11, 
12). These transporters play an important role in vitro 
and in vivo for preventing of glutamate neurotoxicity. 
Ceftriaxone decreases extracellular glutamate levels by 
the enhancement of astrocyte glutamate transporters 
expression (6).  In addition, ceftriaxone has low toxicity. 
A recently published study showed that ceftriaxone is 
neuroprotective during the acute phase of ischemia (13). 
Antagonism of glutamate receptors has been suggested 
as a potential mechanism for the treatment of autism. 
However, regulating glutamate transporter expression 
and activity has an advantage of minimizing the 
pathological impact of glutamate overload while 
maintaining a physiological role of glutamate. It is 
unclear whether the extracellular glutamate transporter 
level is decreased in the disorder. 
Case presentation  
The index patient is a 9 year old boy with autism 
spectrum disorder diagnosed according to Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV). 
He suffered from generalized tonic-clonic epilepsy from 
age 4. He had taken multiple different medications such 
as phenobarbital, sodium valporate, and carbamazepine 
with suf¿cient dosages and durations without favorable 
control of his epilepsy. According to his parents’ reports, 
the patient took ce¿xime 200mg/day to control diarrhea 
about 2 years ago. The seizure episodes were dramatically 
decreased 3 days after starting the medication while the 
there was no change in his anti-epileptic medication 
regime. The seizure episodes were controlled for 
about 5 months, after which the number of seizure 
episodes again increased. His highly educated parents 
administered ce¿xime 200mg/day to control seizure 
again. They reported that seizure attacks were controlled 
markedly after taking ce¿xime for three days. The 
patient was not febrile while the medication trials were 
administered. Both parents reported that they repeated 
this trial for several times to control the seizure episodes 
in the recent years. The epilepsy was controlled in all 
of the trials after taking ce¿xime for 3 to 5 days. Then, 
they discontinued ce¿xime after 7 days. They reported 
that there was a marked decreased in the number of 
seizure attacks as well as aggressive behaviors. Physical 
examination did not show any remarkable ¿nding 
such as fever, headache, or photophobia. Brain MRI 
did not illustrate any abnormal ¿nding. No remarkable 
¿nding was found on laboratory examinations. This is a 
retrospective case report, and caution needs to be used 
in interpreting case reports. His parents provided their 
consent for publication of this report.  
Discussion 
NeuroinÀammation is proposed to contribute to the 
neurobiology of both autism and epilepsy (14-17). 
Recently, anti-inÀammatory and immunosuppressive 
drugs have showed promising therapeutic effects in 
autism (18) and epilepsy. For example, some antibiotics 
including doxycycline, minocycline or tetracycline 
protect against seizures in experimental seizure models 
in rats and mice  (19). However, Clavulanic acid, which 
inhibits bacterial b –lactamases did not affect convulsions 
in acute seizure tests in mice (20).
In several trials, ce¿xime was administered without any 
co-administered medication. Therefore, drug interaction 
was not a likely explanation for this association. A few 
days of seizure control cannot be attributed to a short 
course of ce¿xime but the patient experienced several 
consequent episodes of seizure before administering 
ce¿xime. After administering ce¿xime, these seizure 
episodes stopped. Whenever ce¿xime was not 
administered, seizure episodes happened again.  
Seizures induce brain inÀammation and increases 
interleukin (IL)-1β, potentially disrupting the  blood 
brain barrier (21). Some antibiotics such as minocycline 
may decrease the epileptic seizure through anti-
inÀammatory effects (22), and this effect is a further 
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possible explanation for the effect of ce¿xime on 
epilepsy. 
In view of the limited treatment approaches for autism, 
the proposed role of glutamate in pathophysiology 
of autism (9), the promising ef¿cacy of glutamate 
receptors antagonism for the treatment of autism (23), 
the role of excitatory amino acid transporters in keeping 
extracellular glutamate level below neurotoxic levels 
and the increased expression of the glutamate transporter 
(GLT-1) by ceftriaxone  (7), it seems to be reasonable 
to hypothesize that modulating astrocyte glutamate 
transporter expression by ceftriaxone or ce¿xime 
might be at least partially effective for treating autism 
and epilepsy. Overexpression of vesicular glutamate 
transporter levels in Drosophila causes excess glutamate 
release which leads to excitotoxicity. As the level of 
glutamate is increased in autism, it is proposed as a 
viable target for treating autism. Therefore, targeting 
glutamate by beta lactam antibiotics might be effective 
for treating both autism and seizures. Well controlled 
clinical trials are needed to examine the effects of beta 
lactam antibiotics on animal models of autism plus 
epilepsy.  Cefepime, a fourth-generation cephalosporin 
antibiotic, is associated with seizure risk in some reports 
(24). Future studies should use more objective measures 
such as EEG monitoring and blood drug concentration 
assessment. Consequently, this case report should be 
considered as preliminary and hypothesis generating.
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